Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

Not Applicable

Completed

• Conditions: Drug-Induced Movement Disorder
• Interventions: Other: Telemedicine Consult; Other: In-person Consult

• Registration Number: NCT06060444
• Lead Sponsor: University of Vermont

Brief Summary

In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. Interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in Parkinson's disease and further validation in other movement disorders is necessary.

In this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with DIMDs either in-person or through telemedicine. The investigators will apply the evaluation framework RE-AIM (Reach and Effectiveness, Adoption, Implementation, and Maintenance) to comprehensively assess the factors that may impact study success and program implementation. Mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-26
• Study First Submitted: 2023-06-10
• Study First Submitted QC: 2023-09-23
• Study First Posted: 2023-09-29
• Primary Completion: 2024-09-20
• Study Completion: 2024-10-31
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-03
• Last Update Posted: 2024-11-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• 18 years or older
• Willing and able to provide consent
• Willing to have their Mental Health Clinician (MHC) share sensitive clinical information with the Neurology team
• Able to travel to Neurology clinic
• Have connectivity to Zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as MHC office)

Read More

Exclusion Criteria

• Currently hospitalized
• Neurologist determines patient requires care outside of the scope of the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Telemedicine	Telemedicine Consult	-
In-Person	In-person Consult	Control group

Primary Outcome Measures

Name	Time	Method
Effectiveness; Client Satisfaction Questionnaire-8 (CSQ-8)	12 months	How satisfied are patients with the program

Secondary Outcome Measures

Name	Time	Method
Effectiveness; referral forms and visit notes	12 months	Was there concordance in diagnosis between the MHC and movement disorder specialist
Effectiveness; visit notes	12 months	Was there an impact on care plan
Effectiveness; PROMIS 29+2 V2.1	12 months	What are the impacts on patient health status
Effectiveness; MHC survey and Qualitative Interviews	12 months	Were the MHCs Satisfied with the program

Trial Locations

Locations (1)

University of Vermont Medical Center; 🇺🇸 Burlington, Vermont, United States